anonymous
Guest
anonymous
Guest
Restructuring, low bonus payout, quota.
Dust off those resumes, lay-offs are coming in December.
Dust off those resumes, lay-offs are coming in December.
Restructuring, low bonus payout, quota.
Dust off those resumes, lay-offs are coming in December.
You are an idiot. Quit trying to make people panic.
Supernus now has a reputation of malpractice within the psychiatric space. Good luck launching another medication within psychiatry.
As a psychiatrist, I have no clue where you came up with that idea.
Stock is at $24. There is no need for me to say anything else.
Which has precisely ZERO to do with claims of malpractice. Apparently you have no idea what that term means. So regardless of whether you are an investor, a drug rep, or a clinician - I think you are in the wrong space by investing/promoting/prescribing here.
Gary and Taylor still working on Q4 Quotas
They are cooking up the best bonus plan to pay reps less money
How about this We are 1/3 of the way done with Q4 with no firm baseline. There’s never been a real plan with the adhd sales force. Most reps feel directionless
They are cooking up the best bonus plan to pay reps less money
How about this We are 1/3 of the way done with Q4 with no firm baseline. There’s never been a real plan with the adhd sales force. Most reps feel directionless